Gland B2B Business Model and Growth Strategy

Diversified Business Model with Focus on Growth & Stability Diversified B2B-led Model Across Markets, Complemented by a Targeted B2C Model in India B2B - IP Led B2B (c.96% of FY21 Revenue) B2C (c.4% of FY21 Revenue) B2B Tech Transfer B2B CMO B2C Own Filing Partner Filing • Out-license to marketing partners • Co-development with Partner • Fill and finish service ⚫ Direct marketing of products Overview Long term product supply contracts • Manufacturing by Gland • Loan and license agreements Revenue Model • License and milestone payments . Tech transfer fee . Fixed per unit price • Direct sale of products Selling price per unit dose + Profit Share . Selling price per unit dose + Royalties × х (2) * ANDA Ownership (1) Development (1) IP Ownership (1) Marketing Rights (1) Royalty / Profit Sharing (1) Key Markets Select Clients / Partners Co-owned Global Pharma Companies ४ × × Not Applicable Indian Pharma Companies c.2,000 corporate hospitals, nursing homes & govt. facilities Note: (1). Information reflects typical features of the respective business models in regulated markets. (2). Exhibit batches and stability studies are performed by Gland. 25 GLAND

View entire presentation